Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

Phase 1 Completed 86 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.

Timeline

Start: 2014-09-15
Primary completion: 2017-11-29
Completion: 2017-11-29

Publications

Kublin JG, Murphy SC, Maenza J, Seilie AM, Jain JP, Berger D, Spera D, Zhao R, Soon RL, Czartoski JL, Potochnic MA, Duke E, Chang M, Vaughan A, Kappe SHI, Leong FJ, Pertel P, Prince WT; KAF156 Study Team. Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study. Clin Infect Dis. 2021 Oct 5;73(7):e2407-e2414. doi: 10.1093/cid/ciaa952.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ganaplacide	Small molecule	20 mg	Oral
Subject	Ganaplacide	Small molecule	50 mg	Oral
Subject	Ganaplacide	Small molecule	100 mg	Oral
Subject	Ganaplacide	Small molecule	300 mg	Oral
Subject	Ganaplacide	Small molecule	800 mg	Oral

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

Summary

Timeline

Publications

Drugs

Indications